Gil-Carrasco F, Paczka ZJA, Hayton-Cordero A, Flores-Ojesto E

Language: Spanish
References: 21
Page: 51-56
PDF size: 301.39 Kb.

ABSTRACT

Purpose: To evaluate the safety and efficacy of travoprost, 0.004% solution, when administered during three months for the treatment of elevated intraocular pressure (IOP) in Mexican patients.
Methods: Thirty Mexican patients, with either open-angle glaucoma or ocular hypertension participated in the study. Patients who qualified began a washout period. Travoprost, 0.004% solution, was applied topically once a day for three months.
Results: Travoprost 0.004%, produced a clinically and statistically significant reduction in IOP (P ‹ 0.0001). Maximal decrease in pressure occurred within two weeks and remained essentially unchanged for the remainder of the study. Mean reduction in IOP was between 8.2 and 8.9 mmHg representing decreases of 29.6% to 32.7%. Travoprost was well tolerated. There were no serious adverse events. The most frequent events were ocular hyperaemia (63.3%), flare (16.7%), burning (13.3%), blepharitis (10%), ocular pain (10.0%) and ocular pruritus (10.0%).
Conclusions: Travoprost, 0.004%, administered topically once a day is safe and effective in lowering IOP in patients with open-angle glaucoma and ocular hypertension.

REFERENCES

1. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother 2002; 36:504-511.

2. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989; 48:707-716.

3. Sagara T, Gaton DD, Lindsey JD y cols. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999; 117:794-801.

4. Kelly CR, William GW, Sharif NA. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptor. J Pharmacol Exp Ther 2003; 304:238-245.

5. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther 2002; 18:313-324.

6. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003; 44:715-721.

7. Hellberg MR, Sallee VL, McLaughlin MA y cols. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001; 17:421-432.

8. Netland PA, Landry T, Sullivan EK y cols. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132:472-484.

9. Goldberg I, Cunha-Vaz J, Jakobsen JE y cols. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001; 10:414-422.

10. Orengo-Nania S, Landry T, Von Tress M y cols. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure using timolol 0.5%. Am J Ophthalmol 2001; 132:860-868.

11. Fellman RL, Sullivan RK, Ratliff M y cols. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002; 109:998-1008.

12. Netland PA, Robertson SM, Sullivan EK y cols. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther 2003; 20:149-163.

13. Heijl A, Leske MC, Bengtsson B y cols. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268-1279.

14. Gordon MO, Beiser JA, Brandt JD y cols. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:714-720.

15. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126:498-505.

16. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-440.

17. Hitchings R, Tan J. Target pressure. J Glaucoma 2001; 10 (suppl):68-70.

18. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135:688-703.

19. Noecker RJ, Earl ML, Mundorf T y cols. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003; 20: 121-128.

20. Stewart WC, Kolker AE, Stewart JA y cols. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003; 135:314-320.

21. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003; 19:23-35.